表面根深蒂固的β-固醇体增强了对异二醇诱导的心脏毒性的心脏保护活性,用于大鼠
Shweta Jaiswal1, Md Meraj Anjum1, Dilip Kumar Arya1
1Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, India.
International journal of pharmaceutics
|February 9, 2024
概括
这项研究开发了β-固醇 (BS) 载荷的体 (NS) 和氨酸修饰的体 (BS-HA-NS) 以增强心脏保护. 这两种配方都显著降低了心脏毒性标志物,并保护了心脏组织免受损伤.
科学领域:
- 药理学和纳米技术的应用
- 心血管研究研究心血管研究
- 药物输送系统 药物输送系统
背景情况:
- 心脏毒性 (CT) 对心脏功能构成严重威胁.
- β-固醇 (BS) 具有已知的心脏保护和药理学益处.
- 体药物递送系统为有针对性的治疗干预提供了潜力.
研究的目的:
- 开发和评估β-固醇 (BS) 装载的体 (NS) 和氨酸修饰的体 (BS-HA-NS).
- 提高BS在心脏组织中的特异性和有效性,用于治疗心脏毒性.
- 评估BS-NS和BS-HA-NS对ISO诱导的心肌损伤的心脏保护潜力.
主要方法:
- 使用胆固醇和Tween 80的BS-NS和BS-HA-NS的配方.
- 用尺寸,捕获效率和药物负载来表征尼奥索姆.
- 在体外细胞毒性评估使用MTT测定H9c2心脏细胞.
- 通过测量心脏生物标志物和进行组织组织病理学来评估BS-NS和BS-HA-NS疗效的体内评估.
主要成果:
- 阴体配方表现出有利的物理化学特性 (大小~158 nm,EE~93%,DL~8%).
- BS-NS和BS-HA-NS显著降低了心脏毒性生物标志物 (cTn-I,CK-MB,LDH,AST,MDA) 的使用.
- 组织病理学分析显示,心脏组织的显著修复和保护免受ISO诱导的损伤.
结论:
- 用氨酸 (HA) 修改阴体的表面,可以增强BS向心脏组织的输送.
- 带有BS的体体显示出显著的心脏保护作用和减轻心脏毒性的潜力.
- 基于体的药物输送系统显示出改善心血管疾病治疗结果的前景.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:16Antianginal Drugs: Nitrates and β-Blockers
590
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
590